|
Indications and clinical use:
GrastoFIX® (filgrastim) is indicated for the following:
Cancer Patients Receiving Myelosuppressive Chemotherapy. GrastoFIX® is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.
GrastoFIX® is indicated in adult and pediatric patients with cancer receiving myelosuppressive chemotherapy.
A complete blood count (CBC) and platelet count should be obtained prior to chemotherapy and twice per week during GrastoFIX® therapy to avoid leukocytosis and to monitor the neutrophil count. In phase 3 clinical studies, filgrastim therapy was discontinued
when the ANC was > 10 × 109/L after expected chemotherapy-induced nadir.
Please consult the complete Product Monograph at https://health-products.canada.ca/dpd-bdpp/index-eng.jsp for complete indications, contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The Product Monograph is also available by calling DISpedia, Apotex’s Drug Information Service, at: 1-800-667-4708.
|
